Literature DB >> 7518084

Expression of immunoglobulin and scavenger receptor superfamily domains as chimeric proteins with domains 3 and 4 of CD4 for ligand analysis.

M H Brown1, A N Barclay.   

Abstract

One approach to the analysis of leucocyte cell surface proteins is to express their domains with part of another protein as a carrier. We report the use of two immunoglobulin superfamily (IgSF) domains from rat CD4 (CD4d3 + 4) in producing domains from various superfamilies as chimeric proteins in Chinese hamster ovary cell lines. Four types of construct were successfully expressed containing: (i) the two IgSF domains of CD48; (ii) the IgSF domain of mb-1 which is part of the B cell antigen recognition complex; (iii) a T cell receptor V domain; and (iv) the N-terminal domain of CD5 which belongs to the scavenger receptor superfamily. This CD5 chimeric protein was antigenic for a panel of CD5 mAbs showing that mAbs with functional effects reacted with the N-terminal domain of CD5. The CD48 chimeric protein has been used both as multivalent complexes produced by cross-linking with mAbs recognizing CD4 and in a monomeric form to analyse the kinetics of the interaction between CD48 and CD2 [van der Merwe et al. (1993) EMBO J., 12, 4945-4954].

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518084     DOI: 10.1093/protein/7.4.515

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  24 in total

1.  An unusual Fc receptor-related protein expressed in human centroblasts.

Authors:  Fabio Facchetti; Marina Cella; Silvana Festa; Daved H Fremont; Marco Colonna
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

2.  Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor.

Authors:  Mildred Foster-Cuevas; Gavin J Wright; Michael J Puklavec; Marion H Brown; A Neil Barclay
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels.

Authors:  Richard K Tsai; Pia L Rodriguez; Dennis E Discher
Journal:  Blood Cells Mol Dis       Date:  2010-03-17       Impact factor: 3.039

4.  Multivalent recombinant proteins for probing functions of leucocyte surface proteins such as the CD200 receptor.

Authors:  Despina Voulgaraki; Rita Mitnacht-Kraus; Michelle Letarte; Mildred Foster-Cuevas; Marion H Brown; A Neil Barclay
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

5.  Large-scale screening for novel low-affinity extracellular protein interactions.

Authors:  K Mark Bushell; Christian Söllner; Benjamin Schuster-Boeckler; Alex Bateman; Gavin J Wright
Journal:  Genome Res       Date:  2008-02-22       Impact factor: 9.043

6.  The role of charged residues mediating low affinity protein-protein recognition at the cell surface by CD2.

Authors:  S J Davis; E A Davies; M G Tucknott; E Y Jones; P A van der Merwe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

7.  Determination of the lifetime and force dependence of interactions of single bonds between surface-attached CD2 and CD48 adhesion molecules.

Authors:  A Pierres; A M Benoliel; P Bongrand; P A van der Merwe
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

8.  CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.

Authors:  P A van der Merwe; D L Bodian; S Daenke; P Linsley; S J Davis
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

9.  The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans.

Authors:  G J Wright; M Jones; M J Puklavec; M H Brown; A N Barclay
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

10.  Advances in animal cell recombinant protein production: GS-NS0 expression system.

Authors:  L M Barnes; C M Bentley; A J Dickson
Journal:  Cytotechnology       Date:  2000-02       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.